Ahead of Inderes’ Q3 report, we slightly finetune our estimates, which were already well aligned wit...
JonDeTech redovisade totala rörelseintäkter om 1,5 MSEK (1,3) under Q3’26, varav nettoomsättningen u...
Redeye is positive about Oncopeptides’ directed share issue of about SEK100m, announced on 13 Octobe...
Redeye shares its preview of Vitrolife’s Q3 2026 results, due on October 22
We expect Lassila & Tikanoja’s sales to increase in Q3 driven by Remediation and Industrial Services...
InCoax has announced a fully covered rights issue of approximately SEK45m, providing much-needed fun...
Kabe är marknadsledande i Norden på husvagnar och husbilar.
The first cohort of three patients under the amended protocol has completed the six-week safety eval...
Zefiro Methane Corp. is a listed environmental services company with its operational ...
Redeye gives a short comment on the news that the Xdivane study is fully recruited.
Redeye maintains its view of Freja following solid Q3 KPIs.
Redeye gives an initial comment on the final Phase I data from the CARMA study, published yesterday.
Prelim. Q3 EBITDA of c. € 27m well ahead of eNuW € 18.
Reported EU hybrid import quotas could significantly increase the strategic value of EBRO's Barcelon...
Redeye comments on Hacksaw’s preliminary Q3-result outcome which was below Redeye’s forecasts.
* Q3e: +29% organic growth, EBIT SEK 17m (11m) * '27e-'28e adj.
Plejd reports Q3 2026 numbers on 16 October. We preview our expectations and highlight three proprie...
Redeye research note: Oncopeptides; PDC Platform Crosses the Blood-Brain Barrier
*Competitive electrified models underpin market-share gains and European expansion.
Ahead of Taaleri's Q3 2026 results on 28 October, we make minor negative estimate changes.